Compass Therapeutics Reports Significant Progression-Free Survival Gains for Tovecimig in Biliary Tract Cancer Study
Market Chameleon (Tue, 28-Apr 10:34 AM)
Compass Therapeutics' Tovecimig Delivers 56% Reduction in Progression Risk for Biliary Tract Cancer in Phase 2/3 Study
Market Chameleon (Mon, 27-Apr 7:51 AM)
